STUDY OBJECTIVE: To assess the pharmacokinetics of meropenem administered as a 3-hour infusion. DESIGN: Randomized, crossover, open-label study. SETTING: Clinical research center. SUBJECTS:Six healthy adult male volunteers. INTERVENTION: Each subject received meropenem 0.5 or 2 g every 8 hours as a 3-hour infusion for three doses and then crossed over to the other dosage regimen. MEASUREMENT AND MAIN RESULTS:Pharmacokinetic parameters of both regimens were compared, and no significant differences between 0.5- and 2-g doses for the dose-independent parameters (half-life, clearance, and volume of distribution at steady state) were observed. The regimens displayed dose proportionality and were consistent with that of a traditional 0.5-hour infusion. The 3-hour infusion optimized the pharmacodynamic profile of meropenem and worked within the constraints of stability at room temperature stability. CONCLUSION: Prolonging the percentage of time above the minimum inhibitory concentration is a feasible option with meropenem; however, further studies are needed to quantify how this increase translates to efficacy.
RCT Entities:
STUDY OBJECTIVE: To assess the pharmacokinetics of meropenem administered as a 3-hour infusion. DESIGN: Randomized, crossover, open-label study. SETTING: Clinical research center. SUBJECTS: Six healthy adult male volunteers. INTERVENTION: Each subject received meropenem 0.5 or 2 g every 8 hours as a 3-hour infusion for three doses and then crossed over to the other dosage regimen. MEASUREMENT AND MAIN RESULTS: Pharmacokinetic parameters of both regimens were compared, and no significant differences between 0.5- and 2-g doses for the dose-independent parameters (half-life, clearance, and volume of distribution at steady state) were observed. The regimens displayed dose proportionality and were consistent with that of a traditional 0.5-hour infusion. The 3-hour infusion optimized the pharmacodynamic profile of meropenem and worked within the constraints of stability at room temperature stability. CONCLUSION: Prolonging the percentage of time above the minimum inhibitory concentration is a feasible option with meropenem; however, further studies are needed to quantify how this increase translates to efficacy.
Authors: Christopher M Rubino; Sujata M Bhavnani; Jeffery S Loutit; Brooke Lohse; Michael N Dudley; David C Griffith Journal: Antimicrob Agents Chemother Date: 2018-02-23 Impact factor: 5.191
Authors: Vincent H Tam; Amy N Schilling; Shadi Neshat; Keith Poole; David A Melnick; Elizabeth A Coyle Journal: Antimicrob Agents Chemother Date: 2005-12 Impact factor: 5.191
Authors: K de With; F Allerberger; S Amann; P Apfalter; H-R Brodt; T Eckmanns; M Fellhauer; H K Geiss; O Janata; R Krause; S Lemmen; E Meyer; H Mittermayer; U Porsche; E Presterl; S Reuter; B Sinha; R Strauß; A Wechsler-Fördös; C Wenisch; W V Kern Journal: Infection Date: 2016-06 Impact factor: 3.553
Authors: Christopher M Rubino; Sujata M Bhavnani; Jeffery S Loutit; Elizabeth E Morgan; Dan White; Michael N Dudley; David C Griffith Journal: Antimicrob Agents Chemother Date: 2018-03-27 Impact factor: 5.191
Authors: David C Griffith; Jeffery S Loutit; Elizabeth E Morgan; Stephanie Durso; Michael N Dudley Journal: Antimicrob Agents Chemother Date: 2016-09-23 Impact factor: 5.191
Authors: Federico Perez; Nadim G El Chakhtoura; Krisztina M Papp-Wallace; Brigid M Wilson; Robert A Bonomo Journal: Expert Opin Pharmacother Date: 2016-03-09 Impact factor: 3.889